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Androgen‑deprivation therapy 
and the risk of newly developed 
fractures in patients with prostate 
cancer: a nationwide cohort study 
in Korea
Do Kyung Kim1, Hye Sun Lee2, Ju‑Young Park3, Jong Won Kim4, Hyun Kyu Ahn5, 
Jee Soo Ha6 & Kang Su Cho6*
We evaluated the risk of osteoporosis and fractures associated with androgen deprivation therapy 
(ADT) use and duration in men with prostate cancer. From the nationwide claims database in 
South Korea, a total of 218,203 men with prostate cancer were identified between 2008 and 2017. 
After applying the inclusion and exclusion criteria, a total of 144,670 patients were included in the 
analysis. To adjust for comorbidities between cohorts, 1:1 propensity score matching was used. Cox 
proportional hazard regression models were used to estimate adjusted hazard ratios (HRs) and 95% 
confidence intervals (CIs) of events associated with ADT, after controlling for potential confounding 
factors. In the matched cohort, there were differences in the incidence of newly developed 
osteoporosis (8.79% in the ADT group vs. 7.08% in the non‑ADT group, p < 0.0001) and fractures 
(8.12% in the ADT group vs. 5.04% in the non‑ADT group, p < 0.0001). Age‑adjusted Cox regression 
analysis revealed that the ADT group had a significantly higher risk of osteoporosis (HR, 1.381; 95% CI, 
1.305–1.461; p < 0.0001) and fractures (HR, 1.815; 95% CI, 1.703–1.935; p < 0.0001) compared to the 
non‑ADT group. Furthermore, the risk of osteoporosis and fractures increased as the duration of ADT 
increased. The ADT was associated with an increased risk of osteoporosis and fractures in prostate 
cancer patients. Clinicians who administer ADT for patients with prostate cancer should always be 
mindful of the risk of osteoporosis and fracture, avoid unnecessary ADT, and perform regular bone 
health check‑ups.
Androgen deprivation therapy (ADT) is a common therapy for men with metastatic prostate cancer; those 
with locally advanced disease, in combination with radical surgery or radiation therapy; and those with bio-
chemical recurrence after definitive  treatment1. ADT in the form of orchiectomy, gonadotropin-releasing hor-
mone (GnRH) agonists or antagonists, and anti-androgens has a beneficial effect on the prognosis of advanced 
 disease2–5. Meng et al. identified that nearly 50% of patients with prostate cancer in their study cohort received 
ADT at some point after  diagnosis6.
As the use of ADT increases, potentially serious side effects, including diabetes, cardiovascular disease, 
osteoporosis, and fractures, are also  increasing7–9. Long-term ADT causes significant changes in physiological 
bone turnover, most of which lead to skeletal-related events, including spinal cord compression and pathologic 
 fractures10,11. Of the many adverse effects, osteoporosis and bone fractures are particularly important in relation 
to increased mortality in prostate  cancer12. Therefore, it is important to have accurate information regarding the 
adverse effects of  ADT13,14. Several Western population-based studies revealed that ADT accelerated bone loss 
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within the first 6–12  months15,16, and is associated with constant loss of bone during long-term  treatment17,18. 
By analyzing data from the SEER–Medicare database, Shahinian et al. reported that GnRH-agonist may increase 
the risk of fracture by 1.5-fold and the incidence of hospitalization due to fractures by 1.7-fold7. Abrahamsen 
et al. reported that ADT was associated with a high risk of fracture in Danish men with prostate  cancer19. Alibhai 
et al. also reported that ADT for at least 6 months is associated with an increased risk of fracture, according to 
Canada’s population  database20.
One study showed racial differences in bone mineral density and fractures in men receiving ADT for pros-
tate  cancer21, but only a few studies have been conducted regarding the risk of fracture with ADT in the Asian 
population. To the best of our knowledge, only one population-based study has been conducted concerning 
this issue in an Asian population, in  Taiwan22, raising the possibility that the harmful effects of ADT on the risk 
of fracture in the Asian population may be less than those in the Western population. In the present study, we 
evaluated the risk of newly developed osteoporosis and fracture following ADT in men with prostate cancer 
using the nationwide health insurance claims database in Korea.
Results
Patient characteristics. A total of 144,670 men with prostate cancer fulfilled all inclusion and exclusion 
criteria (Fig. 1). Of these patients, 30,858 men constituted the ADT group and 113,812 men constituted the non-
ADT group. After 1:1 propensity score matching, 30,637 patients from each group were selected. In the matched 
cohort, significant differences were not noted with respect to the baseline covariates between the two groups, 
except for the follow-up duration (1317.42 ± 920.72 days in the ADT group vs. 1453.65 ± 1009.91 days in the 
non-ADT group; p < 0.0001; Table 1).
Osteoporosis risk in ADT vs. non‑ADT groups. In the matched cohort, the ADT group had a higher 
proportion of newly developed osteoporosis than the non-ADT group (8.79% vs. 7.08%, respectively; p < 0.0001; 
Table  1). In addition, age-adjusted Cox regression analysis revealed that the ADT group had a significantly 
higher risk of osteoporosis compared to the non-ADT group (HR, 1.381; 95% CI, 1.305–1.461; p < 0.0001; 
Table 2, Fig. 2A). ADT for < 1 year did not increase the risk of osteoporosis; however, ADT for > 1 year showed 
an increased risk of osteoporosis compared to the non-ADT group. As the duration of ADT increased, the risk of 
osteoporosis also increased (HR, 1.293 for ADT administered for 1–2 years; HR, 1.352 for ADT administered for 
2–3 years, and HR, 1.639 for ADT administered for > 3 years; all p < 0.001; Table 2, Fig. 2B). Even after adjusting 
for index date in the non-ADT group, ADT’s harmful effect in terms of osteoporosis was still apparent (Sup-
plementary Table 3).
Fracture risk in the ADT group vs. the non‑ADT group. In the matched cohort, the ADT group had 
a higher proportion of fracture patients than the non-ADT group (8.12% vs. 5.04%, respectively; p < 0.0001, 
Table 1). In addition, there was a stronger correlation with the risk of fractures in the ADT group compared 
to that in the non-ADT group, as determined by the age-adjusted Cox regression analysis (HR, 1.815; 95% CI, 
1.703–1.935; p < 0.0001; Table 2, Fig. 2C). The analysis of the effect of duration of ADT showed that the risk of 
fracture increased as the duration of ADT increased, except for the period of 1–2 years, 2–3 years, and > 3 years 
(Table 3, Fig. 2D). Age-adjusted Cox regression analysis for fractures after adjusting for the follow-up duration 
Patients with prostate cancer between 2008 and 2017
(n = 218,203)




ADT (n = 30,637) vs. non-ADT (n = 30,637)
Unmatched cohort
(n = 144,670)
ADT (n = 30,858) vs. non-ADT (n = 113,812)
Excluded
 Patients diagnosed with prostate cancer before 2008 
(n = 22,895)
Excluded
 Patients who underwent orchiectomy (n = 1,112)
 Patients with the prior history of osteoporosis or 
fractures and those who underwent event within 90 
days of the index date (n = 34,663)
 Patients taking bisphosphonate and parathyroid 
hormone analogues before the occurrence of an 
event (n = 14,863)
Excluded
 Patients who were excluded by propensity score 
matching (n = 83,396)
Figure 1.  Flow diagram outlining the enrollment of the patient cohort.
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did not reveal significant differences in the results compared to those obtained before adjustment (Supplemen-
tary Table 4).
Risk of osteoporosis and fractures according to anti‑androgen use in the ADT group. In the 
ADT group (n = 30,858), 90.77% of ADT users (n = 28,011) also took anti-androgens, but 9.23% of ADT users 
(n = 2847) did not. To validate the effect of anti-androgens on osteoporosis and fractures, the ADT group was 
subdivided into two groups (anti-androgen users vs. non-users) through propensity score matching according 
to age and duration of ADT, and 2846 patients were selected for each group. There was no difference in the risk 
of osteoporosis between anti-androgen users and non-users in the ADT group (HR, 1.039; 95% CI, 0.850–1.269; 
p = 0.712) and in the risk of fractures (HR, 1.222; 95% CI, 0.992–1.506; p = 0.0599; Supplementary Table 5).
Discussion
In this large population-based study, we found that the use of ADT in the treatment of prostate cancer was asso-
ciated with an increased risk of osteoporosis and fracture. The ADT group had a higher cumulative incidence 
of osteoporosis and fracture than the non-ADT group in the propensity score-matched cohort. In addition, the 
risk of osteoporosis and fracture increased as the duration of ADT increased, although concurrent use of anti-
androgens did not increase the harmful effects of ADT.
Theories regarding osteoporotic fractures include the effect of increased bone turnover on bone strength, 
independent of reduced bone mineral  density23. Normal bone is in a state of equilibrium with ongoing bone 
formation and resorption mediated by osteoblasts and osteoclasts,  respectively24. Androgen deprivation induces 
testosterone and estrogen deficiency, increasing bone turnover and bone resorption, resulting in a decrease in the 
bone mineral density (BMD)25,26. Our previous meta-analysis showed that prostate cancer patients treated with 
ADT showed a significant decrease in the BMD compared to the  controls27. Large-scale population-based studies 
on the correlation between ADT and fracture have been conducted in several Western  countries7,19,20,28,29. Shahin-
ian et al. conducted a study of 50,613 men who survived for more than 5 years after prostate cancer diagnosis, as 
recorded in the database of the National Cancer Institute’s SEER program and  Medicare7. The authors reported 
that patients using ADT experienced fractures more frequently than those not using ADT, and there was a sig-
nificant relationship between fracture risk and cumulative dose of ADT in the first year. Beebe-Dimmer et al. also 
investigated the association between ADT and fracture risk using the SEER-Medicare  dataset28. They reported 
that ADT in elderly men with prostate cancer increased the incidence of fractures, and the effect appeared to 
decrease with increasing time duration since the administration of the last dose of a GnRH agonist. Other 
population-based cohort studies conducted in Denmark, Canada, and New Zealand reported similar results.
Table 1.  Patient demographic characteristics. ADT androgen deprivation therapy, COPD chronic obstructive 
pulmonary disease, SD standard deviation.
Variables








(n = 30,637) p-value
Age, year (mean ± SD) 72.28 ± 8.03 64.10 ± 10.18 < 0.0001 72.19 ± 7.98 72.19 ± 7.98 0.9879
Rheumatoid arthritis, n (%) 1614 (5.23) 6525 (5.73) 0.0007 1604 (5.24) 1582 (5.16) 0.6889
Diabetes mellitus, n (%) 11,392 (36.92) 36,941 (32.46) < 0.0001 11,295 (36.87) 11,323 (36.96) 0.8147
Hyperthyroidism, n (%) 566 (1.83) 2808 (2.47) < 0.0001 564 (1.84) 541 (1.77) 0.4850
Chronic liver disease, n (%) 3148 (10.20) 14,160 (12.44) < 0.0001 3128 (10.21) 3167 (10.34) 0.6038
Chronic kidney disease, n (%) 1130 (3.66) 2450 (2.15) < 0.0001 1111 (3.63) 1076 (3.51) 0.4460
COPD, n (%) 4408 (14.28) 11,254 (9.89) < 0.0001 4379 (14.29) 4419 (14.42) 0.6449
Neurological disease, n (%) 5305 (17.19) 13,392 (11.77) < 0.0001 5261 (17.17) 5303 (17.31) 0.6533
Follow-up duration, day 
(mean ± SD) 1314.39 ± 919.90 1594.08 ± 1035.78 < 0.0001 1317.42 ± 920.72 1453.65 ± 1009.91 < 0.0001
Duration of ADT
< 1 year 10,138 (32.85) 10,060 (32.84)
1–2 years 7875 (25.52) 7803 (25.47)
2–3 years 5006 (16.22) 4968 (16.22)
> 3 years 7839 (25.40) 7806 (25.48)
Osteoporosis, n (%) 2709 (8.78) 6007 (5.28) < 0.0001 2693 (8.79) 2168 (7.08) < 0.0001
Fracture, n (%) 2506 (8.12) 3959 (3.48) < 0.0001 2487 (8.12) 1544 (5.04) < 0.0001
The sites of fracture
Hip 581 (1.88) 771 (0.68) 574 (1.87) 391 (1.28)
Spine 1299 (4.21) 2134 (1.88) 1289 (4.21) 844 (2.75)
Upper extremity 609 (1.97) 1039 (0.91) 607 (1.98) 302 (0.99)
Multiple sites 17 (0.06) 15 (0.01) 17 (0.06) 7 (0.02)
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Nevertheless, it is not known whether the effects of ADT on BMD and fractures vary among races. Morgans 
et al. compared BMD and fracture between African American and Caucasian men receiving ADT for prostate 
cancer to assess whether race-related ADT effects  vary21. They reported that the hip BMD was higher and the 
prevalence of vertebral fractures was lower in African American men receiving ADT for prostate cancer than 
in Caucasian men. Therefore, there may be a racial difference in the effect of ADT on fractures. A few studies 
have discussed the fracture risk among prostate cancer patients in the Asian population receiving ADT, and it 
is unclear whether ADT has a similar effect on the BMD of Asian patients with prostate cancer. Several studies 
have suggested that there are racial differences in the bone density and incidence of fractures between Asian and 
Caucasian  women30–32. Wu et al. conducted a study using the National Health Insurance Program of  Taiwan22. 
They showed that ADT or orchiectomy increased the risk of fracture in Chinese patients with prostate cancer. 
However, the 5-year fracture-free rates were 90.0% in the ADT group and 92.2% in the non-ADT  group22. It has 
been suggested that the effect of ADT on the decrease in the fracture-free rate in the Asian population may not 
be as marked as that reported in Western  studies7,20,33. In our study, the 5-year fracture-free rates in the ADT 
group were 88.26% compared with 93.78% in the non-ADT group. Our results did not differ significantly from 
those of other Western studies. Therefore, it is still questionable whether the effect of ADT on fracture risk varies 
according to race, and additional studies are required to validate these observations.
Evidence-based management for minimizing bone loss in prostate cancer patients with ADT is  important34. 
Bisphosphonates, a human monoclonal antibody (denosumab), and selective estrogen receptor modulators 
(e.g., raloxifene and toremifene) are available for the management of BMD loss by  ADT35. The National Com-
prehensive Cancer Network Guidelines has provided much evidence for the above treatments with respect to 
ADT-induced bone  loss36. Poon et al. found that all the drugs mentioned are effective in reducing the rate of 
bone loss in patients with non-metastatic prostate cancer using ADT, through a systematic review and network 
meta-analysis35. Moreover, clinicians should encourage lifestyle interventions and provide information about 
nutritional supplements to prostate cancer patients using  ADT35. Meanwhile, clinicians administering ADT for 
Table 2.  Age-adjusted Cox regression analysis for predicting osteoporosis in the unmatched (A) and matched 
(B) cohorts. ADT androgen deprivation therapy, CI confidence interval, HR hazard ratio.
Variables
Univariable analysis
Age-adjusted Cox regression analysis
ADT Duration of ADT
HR (95% CIs) p-value HR (95% CIs) p-value HR (95% CIs) Pairwise comparison p-value
(A) Unmatched cohorts











 No Ref. Ref. Ref.
 < 1 year 1.493 (1.356–1.644) < 0.0001
1.043 (0.947–
1.150) 0.3921 Ref.
 1–2 years 2.038 (1.861–2.232) < 0.0001
1.305 (1.190–
1.432) < 0.0001 0.0006 Ref.
 2–3 years 2.088 (1.900–2.295) < 0.0001
1.362 (1.237–
1.498) < 0.0001 < 0.0001 0.51 Ref.
 > 3 years 2.514 (2.367–2.671) < 0.0001
1.599 (1.502–
1.702) < 0.0001 < 0.0001 0.0001 0.003
(B) Matched cohorts











 No Ref. Ref. Ref.
 < 1 year 0.982 (0.887–1.088) 0.7334
1.016 (0.917–
1.125) 0.762 Ref.
 1–2 years 1.317 (1.195–1.452) < 0.0001
1.293 (1.173–
1.426) < 0.0001 0.0002 Ref.
 2–3 years 1.363 (1.232–1.507) < 0.0001
1.352 (1.222–
1.495) < 0.0001 < 0.0001 0.5174 Ref.
> 3 years 1.681 (1.568–1.801) < 0.0001
1.639 (1.529–
1.757) < 0.0001 < 0.0001 < 0.0001 0.003
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prostate cancer patients should consider periodic BMD testing. The USA Endocrine Society and the National 
Comprehensive Cancer Network recommend BMD measurement in men aged 50–69 years with fracture risk 
factors such as use of  ADT36,37.
Our database included almost all prostate cancer patients in Korea during the study period, resulting in a 
large sample size with a relatively long follow-up period. Our study design, based on strict inclusion/exclusion 
criteria of the study cohort and meticulous matching by various covariates, may have been helpful in reducing 
confounding bias. There are few studies on the effect of ADT fracture in patients with prostate cancer in the 
Asian population. In this respect, the present study is very timely. Contrary to our results, previous studies have 
reported that the effects of ADT on fractures in Asian prostate cancer patients may not be as remarkable as those 
reported in the Western  population22. Further studies on the Asian population are needed to prove the difference 
in these results. Bone health care is one of the major issues to address when treating patients with prostate cancer. 
Maintaining bone health throughout prostate cancer is a prerequisite for acceptable quality of life and optimal 
disease course. A more detailed monitoring and treatment guideline of bone health in prostate cancer, while tak-
ing into account the independent factors of fracture risk (i.e. BMD, familiarity for fragility fractures, metabolic 
bone diseases, disability or high risk of fall, and age) depending on the patient’s condition (non-metastatic or 
metastatic disease), should be established.
There were also some limitations. Claim data do not provide clinical information such as tumor stage, tumor 
grade, prostate specific antigen level, and BMD data. The probability of bone metastasis in the ADT group is high, 
and fractures related to bone metastasis could not be excluded from the analysis. However, fractures in prostate 
cancer due to bone metastases are known to account for only 7 to 16 percent of all  fractures38,39. Accordingly, 
the increased risk of fracture from ADT would be maintained even after excluding bone metastasis-related frac-
tures. The present study defined the index date as the start of hormone therapy in the ADT group and the time 
of disease diagnosis in the non-ADT group. This may lead to an immortal time bias for the non-ADT group. 
We applied the exclusion method to resolve immortal time  bias40. Moreover, sensitivity analysis was performed 
using time-dependent Cox regression (time-varying cox regression). Time-dependent Cox regression is the most 
proper way to resolve immortal-time bias, since the model’s time-dependent covariate tracks whether a classifying 
event occurred during the estimation  process41,42. The time-dependent Cox regression model also increases the 
statistical power by using the entire study follow-up data. In addition, we did not distinguish between continuous 
ADT use and intermittent ADT use, which may have impacted the results.
In conclusion, the use of ADT was associated with an increased risk of osteoporosis and fracture in Korean 
patients with prostate cancer. Moreover, our results also indicate that the risk of osteoporosis and fracture 
Figure 2.  Cumulative incidences of osteoporosis and fractures in the matched cohort. (A) Incidence of 
osteoporosis according to the use of ADT. (B) Incidence of osteoporosis according to the duration of ADT use. 
(C) Incidence of fractures according to the use of ADT. (D) Fractures according to the duration of ADT use. 
ADT androgen deprivation therapy.
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increases as the duration of ADT increases. Clinicians who administer ADT for patients with prostate cancer 
should always be mindful of the risk of osteoporosis and fracture, avoid unnecessary ADT, and perform regu-
lar bone health check-ups. Meanwhile, further study investigating racial differences in the effects of ADT on 
fracture is needed.
Materials and methods
Ethics and database. This study was approved by the Institutional Review Board of Yonsei University 
Gangnam Severance Hospital (IRB No. 3-2018-0308) and conducted in accordance with the principles of the 
Declaration of Helsinki. The National Health Insurance System in the Republic of Korea is a universal health 
coverage system that covers more than 95% of Korean residents. The Health Insurance Review and Assessment 
Service (HIRA) collects claim data submitted by healthcare providers for reimbursement. HIRA claims data 
pertains to approximately 46 million patients each  year43.
Inclusion and exclusion criteria. International Classification of Diseases, 10th revision (ICD-10) codes 
were used to identify eligible patients for the analysis. Between January 1, 2008 and December 31, 2017, a total 
of 218,203 men with primary malignant prostate cancer (ICD-10 code C61.0) were identified from the HIRA 
database. Of them, 195,308 were newly diagnosed prostate cancer patients. Patients (n = 1112) who underwent 
orchiectomy were excluded, because surgical castration accounted for an extremely small proportion of patients 
in Korea and we wanted to focus on the effect of medical castration on osteoporosis and fractures. The follow-
ing exclusion criteria were also applied: (1) patients with the prior history of osteoporosis or fractures, or whose 
event occurred within 3 months (n = 34,663) and (2) those who had taken medications such as bisphospho-
nates, calcium supplements, and parathyroid hormone analogues before the events occurred (n = 14,863; Fig. 1). 
Finally, a total of 144,670 patients were included in the analysis.
Table 3.  Age-adjusted Cox regression analysis for predicting fractures in the unmatched (A) and matched (B) 
cohorts. ADT androgen deprivation therapy, CI confidence interval, HR hazard ratio.
Variables
Univariable analysis
Age-adjusted Cox regression analysis
ADT Duration of ADT
HR (95% CIs) p-value HR (95% CIs) p-value HR (95% CIs) Pairwise comparison p-value
(A) Unmatched cohorts











 No Ref. Ref. Ref.
 < 1 year 2.221 (2.009–2.455) < 0.0001
1.512 (1.366–
1.674) < 0.0001 Ref.
 1–2 years 3.109 (2.830–3.417) < 0.0001
1.915 (1.739–
2.108) < 0.0001 0.0004 Ref.
 2–3 years 3.320 (3.018–3.653) < 0.0001
2.092 (1.898–
2.306) < 0.0001 < 0.0001 0.1688 Ref.
 > 3 years 3.237 (3.028–3.460) < 0.0001
1.978 (1.846–
2.120) < 0.0001 < 0.0001 0.5473 0.3114
(B) Matched cohorts











 No Ref. Ref. Ref.
 < 1 year 1.360 (1.221–1.515) < 0.0001
1.453 (1.304–
1.619) < 0.0001 Ref.
 1–2 years 1.894 (1.709–2.098) < 0.0001
1.833 (1.654–
2.031) < 0.0001 0.0005 Ref.
 2–3 years 2.028 (1.828–2.250) < 0.0001
2.006 (1.808–
2.225) < 0.0001 < 0.0001 0.1635 Ref.
 > 3 years 1.995 (1.847–2.155) < 0.0001
1.911 (1.768–
2.064) < 0.0001 < 0.0001 0.4496 0.3802
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Definition of groups, outcomes, and covariates. The study cohort was divided into ADT and non-
ADT groups. The ADT group was defined as those using at least one dose of GnRH agonist or antagonist after 
the diagnosis of prostate cancer. The cumulative dose of ADT was calculated as the sum of the action periods 
of each ADT preparation. Osteoporosis, fracture, and other comorbidities were identified thorough the ICD-10 
diagnostic codes (Supplementary Table 1). Fractures were classified as hip, spine, or upper extremity, according 
to the site.
The incidences of osteoporosis and fracture were ascertained more than 90 days from the index date. Adjust-
ment covariates included patient age, history of rheumatoid arthritis, diabetes, hyperthyroidism, chronic liver dis-
ease, chronic kidney disease, chronic obstructive pulmonary disease (COPD), and neurological disease (stroke, 
Parkinson’s disease, and dementia).
Medication history including ADT, anti-androgen, bisphosphonates, calcium supplements, and parathyroid 
hormone analogues were identified using the billing codes in the HIRA database (Supplementary Table 2).
Statistical analysis. Index date was defined as the date of first ADT use in the ADT group, and as the date 
of prostate cancer diagnosis in the non-ADT group. We defined the end of follow-up as the date that the event 
occurred or the date of the last valid inpatient or outpatient record. A 1:1 exact matching was performed to bal-
ance the comorbidities between groups. For adjustment of comorbidity between cohorts, patients were matched 
using the following criteria: (1) age (± 0 years), (2) the comorbidities (exact match: presence and absence). Sta-
tistical comparisons of continuous variables from patient demographic information were carried out using the 
Student’s t test, and categorical variables were compared using Pearson’s Chi-squared test. Cox proportional 
hazard regression models were used to estimate adjusted hazard ratios (HR) and 95% confidence intervals (CI) 
of events associated with ADT, controlling for potential confounders. Kaplan–Meier curves were generated to 
examine the cumulative incidence of outcomes according to ADT use and the duration of ADT. Meanwhile, 
when there was a difference in the definition of index date between two groups, supplementary analyses were 
performed after adjusting for follow-up duration, as follows. In the ADT group, median time to ADT use from 
the time of prostate cancer diagnosis was 24 days, thus the adjusted index date for non-ADT users was defined 
as the date of prostate cancer diagnosis plus the median time to ADT use in our  study44. A p-value < 0.05 was 
considered statistically significant, and all statistical tests were 2-sided. All study analyses were performed using 
SAS System for Windows, version 9.4.
Received: 4 January 2021; Accepted: 27 April 2021
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